An open trial of OKT3 in patients with multiple sclerosis.

We report our experience with treatment with Muromonab-CD3 (Orthoclone OKT3) of 16 patients with multiple sclerosis (MS) who were in a progressive phase of their disease (n = 13) or in an acute severe attack lasting longer than 1 month without recovery (n = 3). We induced acute severe T-cytopenia wi...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Weinshenker, BG, Bass, B, Karlik, S, Ebers, G, Rice, G
Formatua: Journal article
Hizkuntza:English
Argitaratua: 1991